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Comorbidity weights have become an important tool in
longitudinal outcome studies. They should be tailored to-
ward the population and the disease state under investi-
gation.
OBJECTIVES: The objectives of the study were to de-
velop and validate a comorbidity index for ischemic
stroke patients for use in longitudinal studies.
METHODS: A 5-year retrospective review of all Georgia
Medicaid claims data from 1990 to 1994 was used to de-
tect first time ischemic stroke patients. Ischemic strokes
were defined by three ICD-9-CM code series (433.XX,
434.XX, and 436.XX). Comorbid conditions were mea-
sured from all claims submitted within 12 months prior
the first ischemic stroke event. Half of the stroke cohort
was randomly selected, and multivariate logistic regres-
sion was used to derive a mortality stroke-specific
weighted-index, controlling for age and gender. The
Charlson and stroke-specific indexes were then tested on
the second half of the stroke cohort for their ability to
predict risk of death.
RESULTS: We identified 3,784 ischemic stroke patients
with a mean age of 65 years (range 40 B 102). Of all pa-
tients, 40% died within the 3-year follow-up and 73%
were women. A more concise index with 7 comorbid dis-
ease states was identified. The original Charlson index
has 16 comorbidities. The stepwise multiple logistic re-
gression integer weights for the 7 comorbidities were 2
for CHF, dementia, neoplasia, and renal disease, and 6
for metastatic solid tumor, liver diseases, and AIDS. Fi-
nally, when tested on the second group, the stroke-spe-
cific index showed stepwise increases in the cumulative
mortality attributable to comorbid diseases (p log rank ..;-
2 < 0.001), whereas the Charlson index did not.
CONCLUSION: This shorter stroke-specific index al-
lows for the development of more highly discriminant co-
morbidity models for risk adjustment.
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EVALUATION OF THE COSTS OF CORONARY
HEART DISEASE IN BELGIUM
Annemans L1.2. De Backer W, Van Rompay W', Closon MCJ
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OBJECTIVE: To calculate the cost of ischaemic heart
disease in Belgium.
METHODS: We calculated the cost of acute and follow-
up treatment of coronary heart disease in Belgium, taking
into account a weighted average of current practice.
Costs related to current practice (1996 values) and dis-
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ease progression were taken from the perspective of the
health insurance. Unit costs of ambulatory care were col-
lected through official listings; hospitalisation costs for
heart failure were collected from a database of 58 hospi-
tals (ICD codes 410 to 414). Current practice was ob-
tained through review of 240 patient records in primary
care, post coronary event, during 6 months and through
expert interviews (2 rounds Delphi method). Epidemio-
logical data regarding incidence and distribution of coro-
nary events were obtained via the MONICA WHO
study.
RESULTS: The results indicate that the acute cost of cor-
onary heart disease is equal to 191,933 Bef (37Bef = 1$)
for acute MI, 175,959 Bef for coronary insufficiency, and
159,912 Bef for angina pectoris. Follow-up costs amount
to 47,000 Bef per year, of which 13,000 for drugs, statins
not included. An existing model has been applied and re-
viewed according to Belgian risk predictions to estimate
the cost-effectiveness of statins.
CONCLUSIONS: The study showed that coronary heart
disease is not only expensive in the acute stage but even
more in the follow-up. There are no large differences be-
tween the costs of different coronary events.
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IN-HOSPITAL SURVIVAL OF CONGESTIVE
HEART FAILURE PATIENTS TREATED WITH
DOBUTAMINE OR MILRINONE
Weycker DA, Simons WR
Sanofi Pharmaceuticals. New York, NY, USA
Data indicate that oral positive inotropic agents have a
negative effect on survival. However, evidence suggests
that this conclusion may not apply to intravenous inotro-
pic agents. Further, clinical differences in the action of
these inotropes may lead to variations in their effect on
survival.
OBJECTIVE: This study assesses and compares the odds
of in-hospital survival for patients who received either
amrinone, dobutamine, or milrinone.
METHODS: The data source was a hospital database of
inpatient claims (1995-1996) from 40 U.S. hospitals, in-
cluding information on diagnoses and procedures, costs
and discharge, drug therapies, as well as patient and hos-
pital characteristics. Study eligibility criteria require that
the patient had a diagnosis of congestive heart failure or
underwent a heart by-pass procedure, received at least
one unit of an inotropic agent (dobutamine or milrinone),
and received only one type. Baseline comorbidity mea-
sures were constructed and used as controls for con-
founding covariates such as patient and hospital charac-
teristics, condition severity, complexity of drug therapy,
insurance status, and treatment type. The likelihood of
in-hospital survival was analyzed using logistic regres-
sion. Odds ratios are assessed and compared for each pa-
tient cohort.
RESULTS: The logistic model correctly predicted 79% of
the 308 observed deaths in 1,538 patients selected for
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analysis. The results correctly predicted the effect on sur-
vival due to increased age (negative), condition severity
(negative), complexity of drug therapy (positive), aggres-
sive drug therapy (positive), and a number of life-threat-
ening comorbid conditions (negative); the two inotrope
cohorts indicate a significant difference in in-hospital sur-
vival. Milrinone patients were more than twice as likely
to survive the in-hospital stay than dobutamine patients.
Further, dobutamine patients were twice as likely to sur-
vive than amrinone patients.
CONCLUSION: In-hospital survival varied significantly
by inotropic study cohort. Patients on milrinone had a
higher likelihood of survival.
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PREVENTING CARDIOVASCULAR DISEASE:
IS PRIMARY PREVENTION WITH
PRAVASTATIN WORTH THE MONEY?
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Addition of pravastatin to dietary advice has been shown
by the West of Scotland Coronary Prevention Study
(WOSCOPS) to prevent the transition from health to car-
diovascular disease.
METHODS: An economic analysis was conducted to as-
sess the cost-effectiveness of primary prevention with
pravastatin. Appropriate Canadian risk factor data were
used in an exponential regression model derived from
WOSCOPS data to estimate the rates at which Canadians
transition to cardiovascular disease. The number of tran-
sitions avoided were valued in terms of cost savings to the
Canadian health care system, as well as life years gained.
Canadian costs (1996 CAD $1 = $0.72 US) were based
on ICD-9-CM Ontario Case Cost Project inpatient hospi-
tal data and were discounted at 5% per annum beyond
the first year. The difference between age and gender-
specific Canadian life table survival and post-event sur-
vival obtained from Scottish linkage data was calculated
to estimate life years gained.
RESULTS: The prevention of 303 transitions to CVD,
which implies 3,067 years of life gained, would be
achieved if 10,000 Canadian hypercholesterolaemic men
started treatment. Based on these results, cost-effective-
ness ratios of $10,113ILYG (undiscounted) and $24,223/
LYG (discounted) were obtained. If only high-risk pa-
tients (defined by published consensus statements) are
treated, the ratios drop to between $6,865 and $16,391.
CONCLUSION: In light of published Canadian eco-
nomic analysis guidelines, this constitutes strong evidence
for adoption of primary prevention with pravastatin to
avoid the clinical manifestations of CVD.
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RANDOMIZED EFFECTIVENESS TRIAL
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OBJECTIVE: The purpose of this study was to test the
hypothesis that patients with evidence of left-systolic ven-
tricular dysfunction treated with torsemide would have
fewer hospitalizations for heart failure, improved disease-
specific quality of life, and lower direct inpatient costs
compared to patients treated with furosemide. Pharmaco-
kinetic studies have shown that the bioavailability of
torsemide is more complete and predictable than furo-
semide, especially in patients with heart failure.
METHODS: Prospective, randomized trial. This is an in-
terim analysis of 191 hospitalized patients (65 years of
age::':: 12 SD) who were prescribed torsemide (n = 93) or
furosemide (n = 98) for 1 year. Data were analyzed at 15
months as part of a planned interim intention to treat
analysis. Duration of follow-up did not differ between
treatment groups (233 days::':: 134 SD). Dependent vari-
ables were the numbers of subsequent hospitalizations for
heart failure, other cardiovascular causes, and all causes,
their corresponding count of hospital days, and direct
costs. Disease-specific quality of life was measured using
the Chronic Heart Failure Questionnaire.
RESULTS: Patients treated with torsemide had signifi-
cantly fewer hospitalizations for heart failure (11 vs. 28)
and other cardiovascular causes (20 vs. 48). The differ-
ence in all cause hospitalizations was not significant (77
vs. 107). Hospital days were significantly less for patients
treated with torsemide for all cardiovascular causes only
(91 vs. 222) (p < 0.05). Dyspnea, fatigue, and total dis-
ease-specific quality of life were significantly better for
patients treated with torsemide. Direct inpatient costs for
all cause hospitalizations were $793,460 ($8,532 per pa-
tient) for torsemide and $1,161,617 ($11,617 per pa-
tient) for furosemide.
CONCLUSION: Patients treated with torsemide have
fewer hospitalizations for heart failure and other cardio-
vascular causes, improved dyspnea and fatigue, and
lower direct inpatient health care costs. These effects are
presumably due to the complete and reliable absorption
of torsemide.
